It's fortunate that Pfizer/BioNTech chose the whole spike protein mRNA as their vaccine candidate over the one that focused just on the receptor binding domain

It's fortunate that Pfizer/BioNTech chose the whole spike protein mRNA as their vaccine candidate over the one that focused just on the receptor binding domain -- which the UK mutation changed. Wise choice, and hopefully it will work well against this new variant. https://www.nejm.org/doi/full/10.1056/NEJMoa2027906 https://www.nejm.org/doi/full/10.1056/NEJMoa2027906 Moderna's vaccine was focused on the whole spike protein too. So even though there are crucial mutations in this mutation, both leading vaccine candidates hopefully will still be effective.